Global Prescription Weight Loss Pills Supply, Demand and Key Producers, 2023-2029

Global Prescription Weight Loss Pills Supply, Demand and Key Producers, 2023-2029

The global Prescription Weight Loss Pills market size is expected to reach $ 2259 million by 2029, rising at a market growth of 10.0% CAGR during the forecast period (2023-2029).

Health care professionals use the Body Mass Index (BMI), a measure of people weight in relation to height, to define overweight and obesity. People who have a BMI between 25 and 30 are considered to be overweight. Obesity is defined as having a BMI of 30 or greater. Are overweight, obese, or severely obese, which may increase risk of developing health problems. Obesity is a chronic disease and prescription medications to treat overweight and obesity work in different ways. Prescription weight loss medicines can help obese people lose weight. They are usually prescribed by a doctor when diet and exercise alone are not working. Each of these medicines works differently. People who use these medicines may not feel as hungry. Or they may feel full after eating only a small amount of food. Another type of weight-loss medicine makes it harder for your body to absorb fat. Prescription weight loss drugs can be helpful when used in combination with a low-calorie diet and regular physical activity.

This report studies the global Prescription Weight Loss Pills production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Prescription Weight Loss Pills, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Prescription Weight Loss Pills that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Prescription Weight Loss Pills total production and demand, 2018-2029, (K Units)

Global Prescription Weight Loss Pills total production value, 2018-2029, (USD Million)

Global Prescription Weight Loss Pills production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Prescription Weight Loss Pills consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Prescription Weight Loss Pills domestic production, consumption, key domestic manufacturers and share

Global Prescription Weight Loss Pills production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Prescription Weight Loss Pills production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Prescription Weight Loss Pills production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)

This reports profiles key players in the global Prescription Weight Loss Pills market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Currax Pharmaceuticals (Contrave), VIVUS (Qsymia), Novo Nordisk A/S, Rhythm Pharmaceuticals (Imcivree), Eli Lilly and Company (TRICARE), CHEPLAPHARM (Xenical), Pfizer, Teva Pharmaceutical (Actavis) and Haleon Group (alli), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Prescription Weight Loss Pills market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Prescription Weight Loss Pills Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Prescription Weight Loss Pills Market, Segmentation by Type
Oral Tablets
Oral Capsules
Injections

Global Prescription Weight Loss Pills Market, Segmentation by Application
Hospital
Pharmacy

Companies Profiled:
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)

Key Questions Answered

1. How big is the global Prescription Weight Loss Pills market?

2. What is the demand of the global Prescription Weight Loss Pills market?

3. What is the year over year growth of the global Prescription Weight Loss Pills market?

4. What is the production and production value of the global Prescription Weight Loss Pills market?

5. Who are the key producers in the global Prescription Weight Loss Pills market?

6. What are the growth factors driving the market demand?